Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication

Apyx Medical Corp

2023-Q1 EPS reported -$0.10 revenue$12,142,000

Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).
Net loss $3.5M ($0.10/share) improved from $5.9M loss in Q1 2022; Adjusted EBITDA loss $4.0M.
Raises FY2023 total revenue guidance to $59-62M (prior $58-61M); Advanced Energy $51-54M; net loss expected ~$10.5M.
FDA updated Safety Communication on May 10 clearing Renuvion APR handpiece for subcutaneous soft tissue coagulation post-liposuction.
Closed sale-leaseback of Clearwater facility for $6.6M net cash; secured $35M credit facility with MidCap.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apyx Medical Corp reported the first quarter ended March 31, 2023 results: revenue $12.1 million, net income Net loss attributable to stockholders of $3.5 million. Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $12.1 million
Net income: Net loss attributable to stockholders of $3.5 million
Guidance: raised
Result: reported results

Exact text from the filing

its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023. First Quarter 2023 Financial Summary : • Total revenue of $12.1 million, down 3% year-over-year. ◦ Advanced Energy revenue of $9.7 million, down 10% year-over-year. ◦ OEM revenue of $2.5 million, up 46% year-over-year. • Net loss attributable to

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.